Browsing Tag
Daiichi Sankyo
33 posts
AstraZeneca’s breakthrough in lung cancer treatment: Datopotamab deruxtecan achieves promising survival rates
AstraZeneca’s datopotamab deruxtecan (Dato-DXd), a cutting-edge TROP2-directed antibody-drug conjugate, has demonstrated encouraging overall survival results in the TROPION-Lung01…
Datopotamab deruxtecan shows promise in Phase III trial for NSCLC
AstraZeneca and Daiichi Sankyo have announced promising results from the TROPION-Lung01 Phase III trial, highlighting datopotamab deruxtecan’s potential…
ENHERTU receives EU approval for advanced non-small cell lung cancer
The European Union (EU) has given its nod to ENHERTU (trastuzumab deruxtecan) for the treatment of adult patients…
AstraZeneca and Daiichi Sankyo’s Enhertu recommended for EU approval
AstraZeneca and Daiichi Sankyo’s Enhertu has been recommended for approval in the European Union (EU) for the treatment…
Patritumab Deruxtecan Phase 2 trial unveils encouraging outcomes in metastatic NSCLC
The HERTHENA-Lung01 Phase 2 trial, presented at the 2023 World Conference on Lung Cancer by Daiichi Sankyo, demonstrated…
American Regent’s HEART-FID trial for INJECTAFER fails to meet primary endpoint
American Regent, Inc., a subsidiary of Daiichi Sankyo Group, has announced disappointing results from its phase 3 HEART-FID…
Enhertu shows promising results in DESTINY-PanTumor02 Phase 2 trial
The DESTINY-PanTumor02 Phase II trial revealed high-level results for AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), showcasing clinically…
AstraZeneca, Daiichi Sankyo’s Enhertu approved for breast cancer in China
The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab…
Enhertu EU approval : Daiichi Sankyo, AstraZeneca get approval for HER2 low metastatic breast cancer
Daiichi Sankyo and AstraZeneca have received the approval of the European Union (EU) for their jointly developed Enhertu…
Kite Pharma gets Yescarta approval in Japan for large B-cell lymphoma
Kite Pharma, a subsidiary of Gilead Sciences, and Daiichi Sankyo have received approval from the Japanese Ministry of…